Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | USP1 | O94782 | 10/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608089 | 0.91 | PARP1 (0.41) | GRIN2BUSP1JAK2JAK3 | |
| SCHEMBL3843922 | 0.88 | GRIN2B (0.42) | GRIN2BUSP1VCPGRIN1 | |
| SCHEMBL3848020 | 0.86 | USP1 (0.37) | GRIN2BUSP1JAK2JAK3JAK1 | |
| SCHEMBL3848059 | 0.85 | CHRM3 (0.40) | GRIN2BUSP1JAK2JAK3CHRM3 | |
| SCHEMBL3848056 | 0.85 | CHRM3 (0.40) | GRIN2BUSP1JAK2JAK3CHRM3 | |
| SCHEMBL3845689 | 0.84 | USP1 (0.43) | USP1VCP | |
| SCHEMBL3851160 | 0.80 | ADORA3 (0.38) | GRIN2BUSP1VCP | |
| SCHEMBL13608080 | 0.80 | PARP1 (0.48) | GRIN2BUSP1JAK2JAK3 | |
| SCHEMBL3844922 | 0.79 | GRIN2B (0.41) | GRIN2BUSP1 | |
| SCHEMBL3847751 | 0.78 | MCHR1 (0.37) | GRIN2BUSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | GRIN2B 953/4885USP1 3253/4885VCP 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.